Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 1, 2026

Conditions

Skin Diseases

Interventions

DRUG

Dupilumab

The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.

Trial Locations (1)

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors

lead

Northwestern University

OTHER